Sang Hoon Park

doi:10.4166/kjg.2016.67.3.127

Journal List > Korean J Gastroenterol > v.67(3) > 1007481

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park: Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? – Treatment of Chronic Hepatitis C Genotype 1

Review Article

Korean J Gastroenterol 2016;67(3):127-131.

Published online: 4 October 2016

DOI: https://doi.org/10.4166/kjg.2016.67.3.127

Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? – Treatment of Chronic Hepatitis C Genotype 1

Sang Hoon Park

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Correspondence to: Sang Hoon Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Korea. Tel: +82-2-829-5493, Fax: +82-2-846-4669, E-mail: sanghoon@hallym.or.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV proteins (NS3, NS5A, and NS5B) have been approved for treatment in many countries. Since drugs show advantages and disadvantages, use of a combination of two or more DAAs with different targets or addition of ribavirin in a difficult-to-treat patient shows an SVR rate of ∼90% after 12 weeks of treatment or expanded treatment for 24 weeks. Various types of DAA are awaiting approval which will improve the treatment of chronic hepatitis C virus genotype 1 infection. However, high costs, drug resistance and interactions between various drugs remain to be overcome. With further advances in the development of antiviral agents, it could be expected that in the near future, there will be DAAs that are affordable and cost effective, require shorter treatment duration, effective in a broad range of patients, and have less side effects and drug-drug interactions.

Keywords: Chronic hepatitis C, Treatment, Genotype 1

References

1. Jeong SH, Lee JI, Kim YS, et al. KASL clinical practice guidelines: Management of Hepatitis C. ClinMolHepatol. 2016. in press.

2. Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370:1889–1898.

3. Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370:1483–1493.

4. Jacobson IM, Kwo PY, Kowdley KV, et al. Virologic response rates to all oral fixed-dose combination ledipasvir/sofosbuvir regimens are similar in patients with and without traditional negative predictive factors in phase 3 clinical trials. Hepatology. 2014; 60(Suppl 1):1141A–1142A.

5. Bourliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of 〉500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014; 60(Suppl 1):239A–239A.

6. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015; 62:25–30.

7. Ahn SH, Jeong S, Paik S, et al. Korean patients with genotype 1 and 2 HCV infection achieved over 97% sustained virologic response following 12 weeks of ledipasvir/sofosbuvir or sofosbuvir plus ribavirin. Hepatol Int. 2015; (1 Suppl):9:S72.

8. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370:1594–1603.

9. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370:1983–1992.

10. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombi-tasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016; 64:301–307.

11. Lawitz E, Makara M, Akarca US, et al. Efficacy and safety of ombi-tasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015; 149:971–980.e1.

12. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147:359–365.e1.

13. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370:1973–1982.

14. Manns M, Pol S, Jacobson IM, et al. HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384:1597–1605.

15. Kao JH, Peng CY, Chang TT, et al. All-oral dual therapy with daclatasvir and asunaprevir in patients in Korea and Taiwan with HCV genotype 1b infection. Hepatol Int. 2015; 9(1 Suppl):S74–S75.

16. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 2012; 32(Suppl 1):79–87.

17. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370:211–221.

18. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59:2083–2091.

19. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatmentnaive patients: the COSMOS randomised study. Lancet. 2014; 384:1756–1765.

20. Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology. 2014; 60(Suppl 1):220A.

21. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016. DOI: doi:10.1002/hep.28467. [Epub ahead of print].

22. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2). Hepatology. 2015. DOI: doi:10.1002/hep.28422. [Epub ahead of print].

23. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-monoinfected patients from the French observational cohort ANRS CO22 HEPATHER. J Hepatol. 2015; 62(Suppl 2):S258.

24. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368:1878–1887.

25. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381:2100–2107.

26. Park SH, Park CK, Lee JW, et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multicenter, retrospective observational study. Gut Liver. 2012; 6:98–106.

27. Park SY, Rim MY, Yo IK, et al. Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis. Korean J Gastroenterol. 2012; 60:306–314.

28. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatmentnaive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163:1–13.

29. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an ear-lier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016; 62:32–36.

30. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatmentnaive and treatmentexperienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386:1537–1545.

31. FDA News Release. FDA approves zepatier for treatment of chronic hepatitis C genotypes 1 and 4. [Internet]. Silver Spring, MD: US Food and Drug Administration;2016. [cited 2016 Jan 28]. Available from:. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm.

32. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatmentnaive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015; 163:818–826.

33. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatmentexperienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015; 163:809–817.

34. Feld JJ, Jacobson IM, Hézode C, et al. ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373:2599–2607.

35. Curry MP, O'Leary JG, Bzowej N, et al. ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 373:2618–2628.

TOOLS

Similar articles